Brazil Biosimilars Market Analysis Report 2022 to 2030

Brazil Biosimilars Market Analysis

$ 3999

Brazil's biosimilars market size was valued at $0.4 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 23.2% from 2022 to 2030 and will reach $2.5 Bn in 2030. The market is segmented by product type and indication type. The Brazil Biosimilars market will grow with The increased incidence of chronic illnesses, rising healthcare expenses, and the demand for affordable biologic medicine substitutes. The key market players are Roche (CHE), Novartis (CHE), Pfizer (USA), Sanofi (FRA), Merck (USA), and others.

ID: IN10BRPH027 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Chandani Patel

Buy Now

Brazil Biosimilars Market Executive Summary

The Brazil Biosimilars market size was valued at $0.4 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 23.2% from 2022 to 2030 and will reach $2.5 Bn in 2030. Brazil is the ninth-largest economy in the world, and it boasts one of the biggest and most complicated healthcare systems in the region. The service industry makes up the majority of Brazil's economy, contributing to over 70% of its GDP. Public and commercial healthcare services are both provided under Brazil's mixed healthcare system. Brazilian people can receive free medical treatment through the public healthcare system, known as the Brazilian Unified Health System (SUS), while those who can afford to pay for it can receive care from the private healthcare industry. With a population of over 200 million, the SUS is the world's biggest public healthcare system.

Biosimilars are biological medications that, although not exact replicas of the reference biologics are quite similar to them. Brazil has seen steady growth in the usage of biosimilars over the years as the nation works to improve patient access to low-cost, high-quality medical care. The biosimilar market in Brazil presents significant opportunities for both multinational and local manufacturers, as the country seeks to expand access to affordable and effective treatments for patients.

brazil biosimilars market analysis

Market Dynamics

Market Growth Drivers

In Brazil, several of the original biologic medications that are used to treat illnesses are losing their patent protection, allowing biosimilars to reach the market. Additionally. Because biosimilars are often more affordable than reference biologics, individuals and healthcare systems can save a lot of money by using them. Biosimilars can expand patient access to necessary therapies by lowering costs and increasing availability. The Brazilian government has taken a number of steps to encourage the use of biosimilars, including urging doctors to prescribe them instead of reference biologics and fostering the growth of a biosimilar sector there.

Market Restraints

Brazilian doctors and patients might not be familiar with biosimilars or could worry about their efficacy and safety. Brazil's licensing procedure for biosimilars can be intricate and drawn out, delaying their arrival onto the market.

Furthermore, doctors and patients could have a strong preference for reference biologics, which makes it challenging for biosimilars to obtain market dominance.

Competitive Landscape

Key Players

Roche (CHE)
Novartis (CHE)
Pfizer (USA)
Sanofi (FRA)
Merck (USA)
AbbVie (USA)
Bristol Myers Squibb (USA)
AstraZeneca (GBR)
Johnson & Johnson (USA)
GlaxoSmithKline (GBR)

Healthcare Policies and Regulatory Landscape

The National Health Surveillance Agency (ANVISA) in Brazil is the regulatory body in charge of authorizing biosimilars. The stringent approval procedure for biosimilars calls for extensive preclinical and clinical research.

Similar to reference biologics, biosimilars are paid in Brazil through the Brazilian Public Health System (SUS). The same pricing and reimbursement rules that apply to reference biologics also apply to biosimilars. These rules include a reference price system and prices that producers and the Brazilian government have agreed upon. The Brazilian Biosimilar Policy, which intends to encourage the use of biosimilars in the Brazilian healthcare system, also includes biosimilars.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Brazil Biosimilars Market Segmentation

By Product

The monoclonal antibodies, insulin, granulocyte colony-stimulating factor, erythropoietin, recombinant human growth hormone, etanercept, follitropin, teriparatide, interferons, enoxaparin sodium, glucagon, and calcitonin are among the product categories that make up the biosimilars market. Monoclonal antibodies held a sizable portion of the market in 2020. The market is being driven by elements including the widespread use of monoclonal antibodies in the treatment of autoimmune diseases, cancer, and osteoporosis, as well as the affordability of such treatments.

Monoclonal Antibodies
- Infliximab
- Trastuzumab
- Rituximab
- Adalimumab
- Other monoclonal antibodies (bevacizumab, cetuximab, ranibizumab, denosumab, and eculizumab)
Insulin
Granulocyte Colony-Stimulating Factor
Erythropoietin
Recombinant Human Growth Hormone
Etanercept
Follitropin
Teriparatide
Interferons
Enoxaparin Sodium
Glucagon
Calcitonin

By Indication

The biosimilars market is divided into oncology, autoimmune and inflammatory diseases, chronic illnesses, blood disorders, growth hormone insufficiency, infectious diseases, and other indications based on the indication (infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases). The market's largest sector in 2020 will be oncology. This market is expanding as a result of elements like the reduced cost of biosimilars compared to novel biologics and the increased incidence and prevalence of cancer.

Oncology
Inflammatory & Autoimmune Disorders
Chronic Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Other Indications (infertility, hypoglycemia, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases)

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.